# Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

NCT07053358

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Early Phase 1 |
| **Sponsor** | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| **Enrollment** | 10 participants |

## Key Eligibility Criteria

### Inclusion (6)

- Willing to sign the informed consent, and willing to attend follow-up visits.
- Age e 50
- Diagnosis of active CNV secondary to neovascular AMD
- BCVA ETDRS letters between 5 and 63
- Subjects must have received a minimum of 2 injections within 6 months prior to screening and demonstrated a meaningful response to anti-VEGF therapy

... and 1 more (see full listing online)

### Exclusion (5)

- CNV or macular edema in the study eye secondary to diseases other than nAMD
- Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement
- Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months
- Uncontrolled hypertension defined as average SBP e160 mmHg or an average DBP e100 mmHg
- Uncontrolled diabetes defined as HbA1c \>8.0% within 28 days prior to screening

## Locations (1 total)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China